Advances in Immunotherapy for Head and Neck Squamous Cell Carcinoma.
10.3881/j.issn.1000-503X.16477
- Author:
Yue CAO
1
;
Chun-Mei BAI
2
Author Information
1. Department of Pharmacy,Beijing Health Vocational College,Beijing 101101,China.
2. Department of Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100032,China.
- Publication Type:Review
- Keywords:
head and neck squamous cell carcinoma;
immune checkpoint inhibitor;
induction therapy;
perioperative therapy
- MeSH:
Humans;
Immunotherapy/methods*;
Head and Neck Neoplasms/immunology*;
Squamous Cell Carcinoma of Head and Neck/therapy*
- From:
Acta Academiae Medicinae Sinicae
2025;47(5):850-862
- CountryChina
- Language:English
-
Abstract:
Head and neck squamous cell carcinoma(HNSCC) associated with a poor prognosis and diminished quality of life for patients is the most prevalent pathological type among head and neck tumors. Currently,the standard treatment modalities comprise systemic therapies(including chemotherapy,targeted therapy,and immunotherapy) and local therapies(surgery and radiotherapy).Immunotherapy,characterized by high specificity and low toxicity,is progressively expanding from advanced palliative care to the stage of locally advanced curative treatment and has demonstrated promising efficacy.This review summarizes the latest advances in immunotherapy for HNSCC,aiming to provide reference for optimizing clinical management strategies and facilitating the clinical research.
